Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Sickle Cell Disease Clinical Trial

Official title:

A Pilot Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) as a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05618301
• Other study ID #: 202302190
• Status: Recruiting
• Phase: Phase 1
• Start date: July 7, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2024
• Source: Washington University School of Medicine
• Contact: Zachary Crees, M.D.
• Phone: 314-747-8076
• Email: zcrees[@]wustl.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hematopoietic stem cell (HSC)-based gene therapies now offer curative potential for patients with sickle cell disease (SCD), with decreased toxicity compared to allogeneic hematopoietic cell transplantation. However, effective HSC-based gene therapy depends on collecting sufficient HSCs to generate the therapeutic product, and currently available mobilization regimens carry unacceptable risk for patients with SCD or do not reliably yield optimal numbers of HSCs for gene therapy. The investigators hypothesize that HSC mobilization with motixafortide (CXCR4i) alone and the combination of motixafortide plus natalizumab (VLA-4i) will be safe and tolerable in SCD patients. In addition, the investigators hypothesize that combined CXCR4 and VLA-4 blockade with motixafortide plus natalizumab will result in a rapid, robust, and synergistic increase in HSC mobilization to peripheral blood (PB) in patients with SCD, when compared to motixafortide alone.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Adult patients aged 18-40 years old
• Diagnosis of sickle cell disease (hemoglobin SS or Sß0 genotype)
• Receiving automated RBC exchanges via apheresis-capable central venous access or willing to have apheresis-capable venous access placed.
• Able to hold hydroxyurea, voxelotor, and/or crizanlizumab for at least 60 days prior to mobilization
• Able to hold iron chelation for at least 7 days prior to mobilization
• ECOG performance status = 1
• Normal bone marrow and organ function at screening as defined below:
• Leukocytes = 2,000/uL
• Absolute neutrophil count = 1,500/uL
• Platelets = 75,000/uL
• AST(SGOT)/ALT(SGPT) = 3.0 x IULN at time of screening
• Creatinine clearance = 30 mL/min by Cockcroft-Gault
• Baseline oxygen saturation = 92% on room air
• Left ventricular ejection fraction (LVEF) = 45% (Of note, transthoracic echocardiogram (TTE) will not be required for study. However, if the treating physician has clinical concerns for active cardiac disease for which a TTE is clinically warranted as standard of care, then an EF of = 45% will be required).
• The effects of motixafortide and natalizumab on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation, and 3 months after completion of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 3 months after completion of the study.
• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• Patients may not have a history of receiving the following therapies: prior HCT or prior gene therapy
• Currently receiving concomitant immunosuppressants including 6-mercaptopurine, azathioprine, cyclosporine, methotrexate or concomitant inhibitors of TNF-a.
• Patient may not have a history of significant alloantibodies which, in the opinion of the treating physician and study investigator, significantly increase the risk of participation in this clinical trial.
• Currently receiving any other investigational agents.
• A history of progressive multifocal leukoencephalopathy
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide or natalizumab.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including but not limited to HIV, active/untreated Hepatitis C and/or active/untreated Hepatitis B), ongoing/active vaso-occlusive pain crisis or uncontrolled SCD-related symptoms, symptomatic congestive heart failure, cerebrovascular accident, unstable angina pectoris, or cardiac arrhythmia.
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum/urine pregnancy test within 7 days of study entry and prior to each study agent administration/HSC mobilization.
• Determined by the investigator to be unable or unlikely to comply with the study procedures included in this protocol.

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Drug:
• Motixafortide
Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
• Natalizumab
Natalizumab will be administered as an IV infusion at a flat dose of 300 mg

Procedure:
• Leukapheresis
Leukapheresis consisting of a 1 Blood Volume procedure

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (3)

Lead Sponsor	Collaborator
Washington University School of Medicine	Biogen, BioLineRx, Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability as assessed by the incidence of dose-limiting toxicities (DLTs)	All toxicities will be graded using NCI-CTCAE Version 5.0; A DLT is an event occurring during the DLT period of 28 days following administration of either motixafortide and/or natalizumab that is considered to be at least possibly, probably or definitely related to study treatment by the investigator, and that meets the criteria below: Hematologic criteria; Any Grade 5 adverse event; Any Grade 4 adverse event, excluding Grade 4 hemolysis, bilirubin increase, leukocytosis, erythrocytosis, thrombocytosis, anemia, leukopenia, or febrile neutropenia; Non-hematologic criteria; Any Grade 4 or 5 adverse event.; Any Grade 3 or higher arterial or venous thromboembolic event; Any Grade 2 or 3 adverse event that does not resolve within 4 weeks; with the exception of	Through 28 days following administration of either motixafortide and/or natalizumab (estimated to be 8 weeks and 4 days)
Secondary	Number of CD34+ hematopoietic stem and progenitor cells (HSPCs) mobilized via leukapheresis per liter (L) of total volume (tV) processed following motixafortide alone and motixafortide + natalizumab		Day 2 and Day 60
Secondary	Number of CD34+ hematopoietic stem and progenitor cells (HSPCs) mobilized via leukapheresis per liter (L) of adjusted volume (aV) processed, following motixafortide alone and motixafortide + natalizumab	-The adjusted volume will be calculated as the total volume (tV) processed minus the volumes processed to establish/re-establish the HSC collection interface (iV) to yield an adjusted volume (aV) (i.e. tV-iV=aV). The number of apheresis alarms along with the amount of time, flow rate and volumes processed to establish the interface will be recorded during apheresis and entered into the eCRF. Use of aV will control for the effect of any apheresis alarms; which pause the centrifuge leading to loss of the collection interface.	Day 2 and Day 60
Secondary	Change in kinetics of CD34+ HSC mobilization in response to motixafortide alone and motixafortide + natalizumab in SCD patients, as assessed by CD34+ cells/ul in peripheral blood		From baseline through Day 60
Secondary	Frequency of adverse events	-All adverse events will be graded using NCI-CTCAE Version 5.0	From start of treatment through 8 weeks following completion of all treatment (estimated to be 16 weeks and 4 days)
Secondary	Change in peak CD34+ HSC mobilization in response to motixafortide alone and motixafortide + natalizumab in SCD patients, as assessed by CD34+ cells/ul in peripheral blood		From baseline through Day 60

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine